Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis. Despite the remarkable efficacy of the BCG vaccine in preventing tuberculosis in infants, its effectiveness is scarce in high-burden areas and in adults.1 Therefore, the search...
Invasive fungal infections mainly affect hospitalised patients and are often unrecognised or even underestimated. Mortality among patients with invasive fungal infections remains high (25–60%) despite existing treatments due to patients' background but...
Rezafungin was non-inferior to caspofungin for all-cause mortality, with a potential early treatment benefit, possibly reflecting rezafungin's front-loaded dosing regimen. These findings are of clinical importance in fighting active and aggressive infe...
In their Article, Mary-Claire R Walsh and colleagues1 present results from a phase 2 clinical trial of the TV005 tetravalent dengue vaccine. This trial provides important evidence for the safety and efficacy of the TV005 vaccine across age groups in so...
Bagcchi S. Pertussis cases rise in Denmark. Lancet Infect Dis 2023; 23: e469—In this Newsdesk piece, the quote in the seventh paragraph should read “In Denmark, a monovalent vaccine against pertussis, containing detoxified pertussis toxin, was used unt...
Antivirals against respiratory viruses are optimally administered as early as feasible. Remdesivir, a phosphoramidate prodrug, metabolises into a delayed chain terminator that is an adenosine triphosphate (ATP) analogue. The final active nucleotide, GS...
Among patients with mild-to-moderate COVID-19, VV116 significantly reduced the time to sustained clinical symptom resolution compared with placebo, with no observed safety concerns.
Respiratory syncytial virus (RSV) is a leading cause of severe respiratory illness and death among children worldwide, particularly in children younger than 6 months and in low-income and middle-income countries. Feasible and cost-effective interventio...
We know, not just since Daniel Kahneman's book “Thinking, fast and slow”, how prone we are to coming to conclusions by simplifying information.1 In clinical reasoning, pattern recognition is a valid strategy. However, patterns can be challenged, especi...
160 years after the discovery of its waterborne transmission and 120 years after the development of the first-generation of vaccines, typhoid fever remains a major health threat globally. In this Historical Review, we use WHO's Institutional Repository...
SARS-CoV-2 omicron XBB sublineages efficiently evade immunity from infection or vaccination, requiring vaccine adaptation. Updated monovalent omicron XBB.1.5-containing vaccines were approved in September, 2023. Although preliminary manufacturer data s...
As part of its 2021–2030 sustainable development goals, WHO is targeting zero deaths from dengue virus, an arbovirus that circulates throughout subtropical countries.1 Although health-care access and clinical management are certainly crucial to health ...
As part of its 2021–2030 sustainable development goals, WHO is targeting zero deaths from dengue virus, an arbovirus that circulates throughout subtropical countries.1 Although health-care access and clinical management are certainly crucial to health ...
Pre-XDR resistance is highly prevalent among MDR Mtbc strains in Mozambique and so is bedaquiline resistance; and the frequency of bedaquiline resistance quadrupled over time and was found even in Mtbc strains without fluoroquinolone resistance. Import...
Pre-XDR resistance is highly prevalent among MDR Mtbc strains in Mozambique and so is bedaquiline resistance; and the frequency of bedaquiline resistance quadrupled over time and was found even in Mtbc strains without fluoroquinolone resistance. Import...
WHO now recommends the use of 6–9 month, all-oral regimens for the treatment of multidrug-resistant (MDR) or rifampicin-resistant (RR) tuberculosis.1 Bedaquiline is a key drug in these regimens, and has contributed to substantial improvements in patien...